Refractory Diffuse Large B Cell Lymphoma (DLBCL) (DBCOND0116185)

Identifiers

Synonyms

Diffuse Large B-Cell Lymphoma-Refractory / Refractory Diffuse Large B-cell Lymphoma (DLBCL) / B Cell Refractory Diffuse Large B-Cell Lymphoma / Diffuse Large B Cell Lymphoma Refractory / Refractory Diffuse Large B-Cell Lymphoma / Diffuse Large B-cell Lymphoma Refractory / Refractory Diffuse Large B Cell Lymphoma

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Axicabtagene ciloleucel	A CAR T-cell therapy used to treat adults with large B-cell lymphomas and follicular lymphoma.	B-lymphocyte antigen CD19target
Epcoritamab	A bispecific CD20-directed CD3 T-cell engager used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults.	B-lymphocyte antigen CD20target T-cell surface glycoprotein CD3 epsilon chaintarget
Glofitamab	A bispecific monoclonal antibody directed against CD20 and CD3 which is used for the treatment of relapsed or refractory diffuse large B-cell lymphoma.	B-lymphocyte antigen CD20target T-cell surface glycoprotein CD3target
Lenalidomide	A thalidomide derivative used to treat multiple myeloma and anemia in low to intermediate risk myelodysplastic syndrome.	Prostaglandin G/H synthase 2target Tumor necrosis factor ligand superfamily member 11target Cadherin-5target Protein cereblontarget ATP-dependent translocase ABCB1transporter Tumor necrosis factortarget
Lisocabtagene maraleucel	A CAR T-cell therapy for treatment resistant or more severe B-cell lymphomas.	B-lymphocyte antigen CD19target
Loncastuximab tesirine	An antibody-drug conjugate used for the treatment of relapsed and refractory B-cell lymphomas.	B-lymphocyte antigen CD19target ATP-dependent translocase ABCB1transporter Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme
Tisagenlecleucel	A CAR T cell therapy for relapsed or refractory large B-cell lymphoma and diffuse large B-cell lymphoma.	B-lymphocyte antigen CD19target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06209619	CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma	Golcadomide Rituximab	treatment	1	recruiting
NCT06570447	Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL	Glofitamab Tucidinostat	treatment	2	not_yet_recruiting
NCT01742988	Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma	Fimepinostat Rituximab Venetoclax	treatment	1	completed
NCT02570542	Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)	Carmustine Cytarabine Etoposide Melphalan Plerixafor	treatment	2	active_not_recruiting
NCT05836896	A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies	No drug interventions	treatment	1	recruiting
NCT04792489	DALY II USA/ MB-CART2019.1 for DLBCL	Bendamustine Cyclophosphamide Fludarabine Zamtocabtagene autoleucel	treatment	2	recruiting
NCT02348216	Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma	Axicabtagene ciloleucel Bendamustine Carboplatin Cisplatin Cyclophosphamide Dexamethasone Doxorubicin Etoposide Fludarabine Gemcitabine Ifosfamide Levetiracetam Methylprednisolone Oxaliplatin Prednisone Rituximab Tocilizumab Vincristine	treatment	1 / 2	completed
NCT05121103	A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma	No drug interventions	treatment	1	active_not_recruiting
NCT03367143	Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL	Carboplatin Etoposide Ifosfamide Lenalidomide	treatment	2	unknown_status
NCT02594163	Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma	Bendamustine Brentuximab vedotin Rituximab	treatment	2	terminated
NCT01805557	Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.	No drug interventions	treatment	2 / 3	completed
NCT06033820	Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL	No drug interventions	treatment	2	recruiting
NCT05966233	R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma	Framycetin	treatment	2	withdrawn
NCT06086197	A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL	Anlotinib Gemcitabine Oxaliplatin Rituximab	treatment	2	recruiting
NCT03795571	Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL	Dexamethasone Gemcitabine Lenalidomide Oxaliplatin Rituximab	treatment	1	unknown_status
NCT02142049	Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma	Ibrutinib Lenalidomide	treatment	1 / 2	completed
NCT03589469	Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Loncastuximab tesirine	treatment	2	completed
NCT04703686	Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy	Glofitamab Obinutuzumab	treatment	2	active_not_recruiting
NCT04205409	Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies	Nivolumab	treatment	2	active_not_recruiting
NCT05453396	Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies	Loncastuximab tesirine	treatment	2	recruiting
NCT05828589	A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies	No drug interventions	treatment	1	recruiting
NCT06343376	Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies	Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT06458439	Epcoritamab-CAR T Cells for Large B-cell Lymphomas	Epcoritamab	treatment	2	recruiting
NCT06649812	Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma	No drug interventions	treatment	2	not_yet_recruiting
NCT01955499	Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	Ibrutinib Lenalidomide	treatment	1	active_not_recruiting
NCT05359211	NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma	Cyclophosphamide Fludarabine Lisocabtagene maraleucel	treatment	1	recruiting
NCT03321643	Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma	Atezolizumab Gemcitabine Oxaliplatin Rituximab	treatment	1	active_not_recruiting
NCT03259503	Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant	Busulfan Gemcitabine Mechlorethamine Olaparib Rituximab Vorinostat	treatment	1	active_not_recruiting
NCT04384484	Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Gemcitabine Loncastuximab tesirine Oxaliplatin Rituximab	treatment	3	recruiting
NCT05267054	Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab	Ociperlimab Rituximab Tislelizumab	treatment	1 / 2	active_not_recruiting
NCT03488251	PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma	Gemcitabine Oxaliplatin	treatment	2	terminated
NCT02568553	Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma	Blinatumomab Lenalidomide Muromonab	treatment	1	active_not_recruiting
NCT04870853	Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy	No drug interventions	Not Available	Not Available	recruiting
NCT03401853	Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma	Obinutuzumab Pembrolizumab Rituximab	treatment	2	active_not_recruiting
NCT03305445	Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL	Ipilimumab Nivolumab	treatment	1	completed
NCT01959698	Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma	Beta-D-Glucose Carboplatin Carfilzomib Cyclophosphamide Etoposide Ifosfamide Rituximab	treatment	1	active_not_recruiting
NCT02628405	R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma	Beta-D-Glucose Carboplatin Cyclophosphamide Etoposide Ifosfamide Lenalidomide Rituximab	treatment	1 / 2	active_not_recruiting
NCT05052528	Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Cyclophosphamide Fludarabine Rituximab	treatment	1	recruiting
NCT04156828	Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma	Carboplatin Copanlisib Dexamethasone Filgrastim Gemcitabine Pegfilgrastim Rituximab	treatment	1	terminated
NCT03103971	huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia	Cyclophosphamide Fludarabine	treatment	1	terminated
NCT01431209	Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant	Ruxolitinib	treatment	2	completed
NCT05633615	Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	Axicabtagene ciloleucel Cyclophosphamide Fludarabine Lisocabtagene maraleucel Mosunetuzumab Muromonab Polatuzumab vedotin Tisagenlecleucel	treatment	2	recruiting
NCT04856137	A Phase I/II Study of Diffuse Large B-cell Lymphoma	Filgrastim Paclitaxel Rituximab Ruxolitinib	treatment	1 / 2	not_yet_recruiting
NCT05890352	Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment	Lenalidomide Tafasitamab Tazemetostat Zanubrutinib	treatment	2	recruiting
NCT03688152	A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma	Parsaclisib Uzansertib	treatment	1	completed
NCT05228249	Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma	Beta-D-Glucose Carmustine Cytarabine Etoposide Loncastuximab tesirine Mechlorethamine	treatment	1	withdrawn
NCT04995536	CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL	No drug interventions	treatment	1	withdrawn
NCT03287817	CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma	AUTO3	treatment	1 / 2	completed
NCT04659434	Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL	Sintilimab	treatment	2	not_yet_recruiting
NCT02366663	BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL	Carmustine Cytarabine Etoposide Melphalan Rituximab	treatment	3	terminated
NCT02992522	Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	Lenalidomide Obinutuzumab Venetoclax	treatment	1	active_not_recruiting
NCT02051257	Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma	No drug interventions	treatment	1	active_not_recruiting
NCT02926833	Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	Atezolizumab Axicabtagene ciloleucel Cyclophosphamide Fludarabine	treatment	1 / 2	completed
NCT05077527	Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma	Axicabtagene ciloleucel Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT03150329	Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.	Pembrolizumab Vorinostat	treatment	1	active_not_recruiting
NCT04007029	Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	Cyclophosphamide Fludarabine Tocilizumab	treatment	1	recruiting
NCT03892044	Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma	Duvelisib Nivolumab	treatment	1	completed
NCT05068440	Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib	Zanubrutinib	treatment	2	recruiting
NCT01434472	High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma	Cyclosporine Fludarabine Mycophenolate mofetil Rituximab	treatment	2	terminated
NCT04285268	Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Bortezomib Bortezomib D-mannitol Rituximab Venetoclax	treatment	2	withdrawn
NCT02658968	Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)	Lilotomab Lutetium Lu-177 Tetulomab tetraxetan Lu-177	treatment	1	completed
NCT04833114	Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)	Carboplatin Etoposide Ifosfamide Polatuzumab vedotin Rituximab	treatment	3	recruiting
NCT03418038	Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia	Beta-D-Glucose Carboplatin Chloride ion Cisplatin Cyclophosphamide Cytarabine Decitabine Dexamethasone Etoposide Gemcitabine Ifosfamide Oxaliplatin Platinum Rituximab	treatment	2	recruiting
NCT05075603	Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy	Axicabtagene ciloleucel Efineptakin alfa Lisocabtagene maraleucel Tisagenlecleucel	treatment	1	recruiting
NCT05272384	Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma	Cedazuridine Decitabine Nivolumab	treatment	1	recruiting
NCT06191887	B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies	Bendamustine Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT03272633	Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies	No drug interventions	treatment	0	terminated
NCT05672251	Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Loncastuximab tesirine Mosunetuzumab Muromonab	treatment	2	recruiting
NCT02572453	Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL	Onalespib	treatment	2	terminated
NCT02706405	JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	Cyclophosphamide Durvalumab Fludarabine JCAR014	treatment	1	terminated
NCT05800405	Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma	No drug interventions	treatment	0	recruiting
NCT06047197	Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma	No drug interventions	treatment	1	recruiting
NCT03136497	A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	Ibrutinib Rituximab Venetoclax	treatment	1	active_not_recruiting
NCT03309878	Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma	Mogamulizumab Pembrolizumab	treatment	1 / 2	completed
NCT02405078	Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma	Fludeoxyglucose (18F) Fluorine F-18	diagnostic	0	completed
NCT02219737	Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma	Beta-D-Glucose Carboplatin Cyclophosphamide Etoposide Ibrutinib Ifosfamide Rituximab	treatment	1	completed
NCT04432506	Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma	Anakinra Axicabtagene ciloleucel Cyclophosphamide Fludarabine	treatment	2	completed
NCT06536049	Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma	Epcoritamab Ibrutinib	treatment	1 / 2	not_yet_recruiting
NCT04890236	Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study	Duvelisib Tisagenlecleucel	treatment	0	recruiting
NCT03484819	Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma	Copanlisib Nivolumab	treatment	2	active_not_recruiting
NCT01865617	Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia	No drug interventions	treatment	1 / 2	completed
NCT04920617	DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Cyclophosphamide Maveropepimut-S Pembrolizumab	treatment	2	recruiting
NCT03583424	Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma	Beta-D-Glucose Carmustine Cytarabine Etoposide Mechlorethamine Venetoclax	treatment	1 / 2	unknown_status
NCT03015896	Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma	Lenalidomide Nivolumab	treatment	1 / 2	active_not_recruiting
NCT04572763	Copanlisib Plus Venetoclax in R/R DLBCL	Copanlisib Venetoclax	treatment	1 / 2	active_not_recruiting
NCT02976857	A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects	No drug interventions	treatment	1	completed
NCT02077166	Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Ibrutinib Lenalidomide Rituximab	treatment	1 / 2	completed
NCT04665765	Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Beta-D-Glucose Carboplatin Cyclophosphamide Etoposide Ifosfamide Polatuzumab vedotin Rituximab	treatment	2	active_not_recruiting
NCT04804865	Secondary Prognostic Index in RefrActory Lymphoma	No drug interventions	Not Available	Not Available	unknown_status
NCT02950220	Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	Ibrutinib Pembrolizumab	treatment	1	completed
NCT03579927	CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma	Beta-D-Glucose Carmustine Cytarabine Etoposide Filgrastim Mechlorethamine Natural Killer Cell Rituximab	treatment	1 / 2	withdrawn
NCT03277729	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	Cyclophosphamide Fludarabine	treatment	1 / 2	active_not_recruiting
NCT03019640	Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma	Allogeneic natural killer cells Beta-D-Glucose Carmustine Cytarabine Etoposide Filgrastim Lenalidomide Mechlorethamine Natural Killer Cell Rituximab	treatment	2	completed
NCT03440567	Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma	Avelumab Carboplatin Cyclophosphamide Etoposide Ibrutinib Ifosfamide Rituximab Utomilumab	treatment	1	active_not_recruiting
NCT02874404	TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Ibrutinib Umbralisib	treatment	2	completed
NCT03038672	Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas	Nivolumab Varlilumab	treatment	2	active_not_recruiting
NCT03479268	Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	Ibrutinib Pevonedistat	treatment	1	active_not_recruiting
NCT01897012	Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas	Alisertib Romidepsin	treatment	1	completed
NCT04409314	Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy	Fluoroazomycin arabinoside F-18	Not Available	Not Available	completed
NCT03558750	Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma	Lenalidomide Nivolumab Rituximab	treatment	1	terminated
NCT03422523	Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy	Atezolizumab Gemcitabine Oxaliplatin Rituximab	treatment	2	terminated
NCT04205838	Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma	Anakinra Axicabtagene ciloleucel Cyclophosphamide Fludarabine	prevention	2	recruiting
NCT06271057	Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse	Golcadomide	treatment	2	recruiting